What one share of Septerna holds
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (“GPCR”) oral small molecule drug discovery powered by our proprietary Native Complex Platform®.
Septerna’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.21 |
|---|---|
| Profit | −$0.54 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | $2.35 |
| Cash and investments | $11.31 |
| Book value | $8.47 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $0.07 | $0.29 | $1.32 | −$19.11 | — | −$12.11 |
| 2024 | $0.11 | −$7.26 | $0.21 | −$7.03 | — | — |
| 2025 | $1.04 | −$1.10 | $0.01 | $2.48 | — | $8.52 |
Common questions about Septerna
How much does one share of Septerna earn?
Over the last 12 months, Septerna lost $0.54 for each share on $2.21 of sales.
Does Septerna pay a dividend?
Septerna didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Septerna’s book value per share?
Septerna’s book value is $8.47 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Septerna have?
Each share of Septerna has $11.31 of cash and investments, as of June 30, 2026.
What is Septerna’s free cash flow per share?
$2.35 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.